Bolt Biotherapeutics (BOLT) Return on Equity (2020 - 2025)
Bolt Biotherapeutics' Return on Equity history spans 6 years, with the latest figure at 1.21% for Q3 2025.
- For Q3 2025, Return on Equity fell 32.0% year-over-year to 1.21%; the TTM value through Sep 2025 reached 1.21%, down 32.0%, while the annual FY2024 figure was 0.8%, 31.0% down from the prior year.
- Return on Equity for Q3 2025 was 1.21% at Bolt Biotherapeutics, down from 1.19% in the prior quarter.
- Across five years, Return on Equity topped out at 0.24% in Q2 2021 and bottomed at 1.22% in Q1 2025.
- The 5-year median for Return on Equity is 0.53% (2023), against an average of 0.65%.
- The largest annual shift saw Return on Equity crashed -90bps in 2021 before it rose 18bps in 2022.
- A 5-year view of Return on Equity shows it stood at 0.35% in 2021, then tumbled by -39bps to 0.49% in 2022, then fell by -17bps to 0.57% in 2023, then crashed by -83bps to 1.05% in 2024, then decreased by -15bps to 1.21% in 2025.
- Per Business Quant, the three most recent readings for BOLT's Return on Equity are 1.21% (Q3 2025), 1.19% (Q2 2025), and 1.22% (Q1 2025).